[ad_1]
Tianjing, China, January 8, 2022 /PRNewswire/ – CanSino Biologics Inc. (“CanSinoBIO”) (SSE: 688185, HKEX: 06185) announced that the National Medical Products Administration China (“NMPA”) approved its ACYW135 meningococcal conjugate vaccine (CRM197) (“MCV4”, trade name: Menhycia™), making it the first such vaccine to be authorized China.
Using CanSinoBIO’s industry-leading synthetic biotechnology and formulation technology platform, Menhycia™ covalently binds the common pathogenic meningococcal serogroups A, C, W135 and Y with the carrier protein CRM197.Currently, Menhycia™ is the initial vaccine product containing these four serogroups China. exist December 2019, NMPA granted Menhycia™ priority review status, making it the first MCV4 to be included in the priority review list China.
The approval marks an important step in accelerating development China’s Meningococcal vaccine immunization strategy. Menhycia™ provides protection for a wide range of age groups, including children from 3 months to 3 years (47 months), through…
The full story can be found on Benzinga.com
[ad_2]
Source link
